All In Biotech

Drug Trial Radar · NCT06703658

A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus

A Phase I, Randomised, Single-blind, Placebo-controlled, Single and Repeated Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5004 in Healthy Japanese Participants and With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Nov 2, 2024

Primary completion

Mar 13, 2025

Study completion Mar 13, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase I study will gather important information on the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5004 in both healthy Japanese participants and Japanese participants with T2DM.

Conditions

  • Healthy Participants
  • Type 2 Diabetes

Interventions

  • AZD5004(Part A)Drug

    Single dose of AZD5004 oral on Day1

  • Placebo(Part A)Drug

    Single dose of placebo oral on Day1

  • AZD5004(Part B)Drug

    AZD5004 will be administered as an oral tablet once daily.

  • Placebo(Part B)Drug

    Placebo will be administered as an oral tablet once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PartA: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: From screening (Day -28) to last follow up visit (Day 8)
  2. PartB: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: From screening (Day -28) to last follow up visit (Day 119 )

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Osaka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.